STUDY OF THE NATURAL HISTORY OF CHRONIC NON-A, NON-B HEPATITIS

记录良好的慢性非甲非乙型（NANB）肝炎患者 正在进行评估，以确定长期的自然历史， 这种常见的慢性肝病。 一群 患者可以评估针对此的实验性疗法 疾病 在一项初步研究中，10名患者接受了α- 干扰素 随访显示，6名患者似乎长期 肝炎明显完全缓解了 2例病例的 反应是有利的，但暂时的，2名患者没有反应 根本 一项前瞻性、随机化、安慰剂对照、双- 人类α-干扰素治疗慢性阻塞性肺疾病6个月的盲法试验 慢性非乙型肝炎患者正在进行中。 四十一 患者已入组，26例已完成6个月的 治疗至今。 13例接受干扰素治疗的患者中有12例 血清ALT活性有所下降，其中7例ALT恢复 治疗后恢复到正常水平。 平均血清ALT活性不 在任何安慰剂治疗的患者中变得正常。 干扰素 一般耐受良好，类似的不良发展是 在干扰素和安慰剂治疗组中观察到。

Patients with well-documented chronic non-A, non-B (NANB) hepatitis are being evaluated to determine the long-term natural history of this common form of chronic liver disease. A cohort of such patients are available to evaluate experimental therapies for this disease. In a pilot study, 10 patients were treated with alpha- interferon. Follow up shows that 6 seem to have had a long-term apparently complete remission of the hepatitis. In 2 cases the response was favorable but temporary and 2 patients did not respond at all. A prospective, randomized, placebo-controlled, double- blind trial of a six month course of human alpha interferon in patients with chronic NANB hepatitis is underway. Forty one patients have been entered and 26 have completed 6 months of treatment so far. 12 of 13 patients treated with interferon showed some decrease in serum ALT activity and in 7 of these, ALT returned to normal levels after treatment. Mean serum ALT activity did not become normal in any placebo-treated patients. Interferon was generally well tolerated and similar untoward developments were noted in interferon and placebo treated groups.